BR112018072286A2 - medida direcionada de atividade transcricional relacionada a receptores de hormônios - Google Patents
medida direcionada de atividade transcricional relacionada a receptores de hormôniosInfo
- Publication number
- BR112018072286A2 BR112018072286A2 BR112018072286-3A BR112018072286A BR112018072286A2 BR 112018072286 A2 BR112018072286 A2 BR 112018072286A2 BR 112018072286 A BR112018072286 A BR 112018072286A BR 112018072286 A2 BR112018072286 A2 BR 112018072286A2
- Authority
- BR
- Brazil
- Prior art keywords
- index
- seter
- hormone receptor
- transcriptional activity
- endocrine
- Prior art date
Links
- 108091008039 hormone receptors Proteins 0.000 title 1
- 230000002103 transcriptional effect Effects 0.000 title 1
- 238000009261 endocrine therapy Methods 0.000 abstract 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 101150064205 ESR1 gene Proteins 0.000 abstract 1
- 102100038595 Estrogen receptor Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100025803 Progesterone receptor Human genes 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 108090000468 progesterone receptors Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 101150076141 rn gene Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B10/00—ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Abstract
trata-se de métodos para determinar a sensibilidade tumoral à terapia hormonal (endócrina) com base em um índice de genes relacionados ao receptor de estrogênio (er) e ao receptor de progesterona (pr), referido como o índice de sensibilidade à terapia endócrina (índice seter/pr), e pode ter uma consideração adicional para a proporção de transcrições de rna de gene er (esr1) que contêm uma mutação relativa ao valor do índice seter/pr. proporcionam-se, ainda, métodos para tratar pacientes com câncer de mama determinados como sendo sensíveis a uma terapia endócrina pelo índice seter/pr.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662329774P | 2016-04-29 | 2016-04-29 | |
US62/329,774 | 2016-04-29 | ||
PCT/US2017/030077 WO2017189976A1 (en) | 2016-04-29 | 2017-04-28 | Targeted measure of transcriptional activity related to hormone receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018072286A2 true BR112018072286A2 (pt) | 2019-02-12 |
Family
ID=60161204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018072286-3A BR112018072286A2 (pt) | 2016-04-29 | 2017-04-28 | medida direcionada de atividade transcricional relacionada a receptores de hormônios |
Country Status (9)
Country | Link |
---|---|
US (2) | US11459617B2 (pt) |
EP (2) | EP3449017B1 (pt) |
JP (1) | JP7131773B2 (pt) |
BR (1) | BR112018072286A2 (pt) |
CA (1) | CA3022377A1 (pt) |
DK (1) | DK3449017T3 (pt) |
IL (1) | IL262643B2 (pt) |
PL (1) | PL3449017T3 (pt) |
WO (1) | WO2017189976A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107760787B (zh) * | 2017-12-01 | 2020-05-19 | 洛阳科赫医疗器械有限公司 | 一种乳腺癌分子分型实时荧光多重pcr引物及试剂盒与应用 |
GB202116745D0 (en) * | 2021-11-19 | 2022-01-05 | Institute Of Cancer Res Royal Cancer Hospital | Prognostic and treatment response predictive method |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2202114A (en) | 1937-08-09 | 1940-05-28 | Morf Ernest | Exterior operating member for watertight watches |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
AU7326594A (en) | 1993-07-09 | 1995-02-06 | Synergen, Inc. | Recombinant ctla4 polypeptides and methods for making the same |
US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5716784A (en) | 1996-02-05 | 1998-02-10 | The Perkin-Elmer Corporation | Fluorescence detection assay for homogeneous PCR hybridization systems |
US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
NZ512553A (en) | 1998-12-23 | 2004-02-27 | Pfizer | Human monoclonal antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4) |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
CA2519980C (en) | 2003-04-01 | 2012-04-10 | Laboratoires Besins International | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
US8158574B2 (en) | 2004-10-07 | 2012-04-17 | Cdg Therapeutics, Inc. | Compositions and methods to prevent cancer with cupredoxins |
EP1937251A2 (en) | 2005-04-25 | 2008-07-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
AU2006246241A1 (en) | 2005-05-13 | 2006-11-16 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
US20070134688A1 (en) * | 2005-09-09 | 2007-06-14 | The Board Of Regents Of The University Of Texas System | Calculated index of genomic expression of estrogen receptor (er) and er-related genes |
JP5449775B2 (ja) | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
CA2688049A1 (en) | 2007-05-31 | 2008-12-04 | Dako Denmark A/S | Methods for utilizing esr copy number changes in breast cancer treatments and prognoses |
SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
US8747847B2 (en) | 2008-02-11 | 2014-06-10 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
EP2297359B1 (en) | 2008-05-30 | 2013-11-13 | The University of North Carolina at Chapel Hill | Gene expression profiles to predict breast cancer outcomes |
US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
EP2425021A4 (en) * | 2009-05-01 | 2013-03-06 | Nuvera Biosciences Inc | INDEX OF GENOMEXPRESSION OF ESTROGEN RECEPTOR (ER) AND ER-ASSOCIATED GENES |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
EP2534267B1 (en) | 2010-02-12 | 2018-04-11 | Raindance Technologies, Inc. | Digital analyte analysis |
AU2011217770B2 (en) | 2010-02-19 | 2016-02-04 | Xencor, Inc. | Novel CTLA4-IG immunoadhesins |
BR122020016370B1 (pt) * | 2010-03-31 | 2021-05-11 | Sividon Diagnostics Gmbh | métodos para predizer um resultado de câncer de mama em um tumor de mama positivo para receptor de estrogênio e negativo para her2 de um paciente com câncer de mama |
US20130084570A1 (en) * | 2010-04-14 | 2013-04-04 | The Board Of Regents Of The University Of Texas Sy | Methods of evaluating response to cancer therapy |
EP2659005A4 (en) * | 2010-12-28 | 2016-08-24 | Caris Mpi Inc | MOLECULAR PROFILING OF CANCER |
CA2854665A1 (en) | 2011-11-10 | 2013-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene expression signatures of neoplasm responsiveness to therapy |
WO2013106913A1 (en) | 2012-01-19 | 2013-07-25 | University Health Network | Biomarkers for breast cancer prognosis and treatment |
NO2694769T3 (pt) | 2012-03-06 | 2018-03-03 | ||
US9803245B2 (en) | 2012-03-14 | 2017-10-31 | University Health Network | Signature for predicting clinical outcome in human HER2+ breast cancer |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
US9155727B2 (en) | 2013-05-28 | 2015-10-13 | Astrazeneca Ab | Chemical compounds |
WO2015016718A1 (en) | 2013-08-02 | 2015-02-05 | Bionovion Holding B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
CN106488767A (zh) * | 2014-03-13 | 2017-03-08 | 豪夫迈·罗氏有限公司 | 调节雌激素受体突变体的方法和组合物 |
WO2015164501A2 (en) * | 2014-04-23 | 2015-10-29 | Myriad Genetics, Inc. | Cancer prognosis signatures |
WO2016042164A1 (en) * | 2014-09-19 | 2016-03-24 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Unidv. Trinity Of Queen Elizabeth, Near Dublin | A method of predicting risk of recurrence of cancer |
AU2015333687B2 (en) | 2014-10-14 | 2021-03-18 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to PD-L1 and uses thereof |
-
2017
- 2017-04-28 US US16/097,102 patent/US11459617B2/en active Active
- 2017-04-28 EP EP17790517.1A patent/EP3449017B1/en active Active
- 2017-04-28 EP EP21215961.0A patent/EP4029950A1/en active Pending
- 2017-04-28 BR BR112018072286-3A patent/BR112018072286A2/pt unknown
- 2017-04-28 IL IL262643A patent/IL262643B2/en unknown
- 2017-04-28 DK DK17790517.1T patent/DK3449017T3/da active
- 2017-04-28 JP JP2018556452A patent/JP7131773B2/ja active Active
- 2017-04-28 PL PL17790517T patent/PL3449017T3/pl unknown
- 2017-04-28 CA CA3022377A patent/CA3022377A1/en active Pending
- 2017-04-28 WO PCT/US2017/030077 patent/WO2017189976A1/en unknown
-
2022
- 2022-08-25 US US17/822,332 patent/US20220403474A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220403474A1 (en) | 2022-12-22 |
EP4029950A1 (en) | 2022-07-20 |
EP3449017A1 (en) | 2019-03-06 |
IL262643A (en) | 2018-12-31 |
PL3449017T3 (pl) | 2022-06-27 |
US11459617B2 (en) | 2022-10-04 |
EP3449017B1 (en) | 2021-12-22 |
JP7131773B2 (ja) | 2022-09-06 |
US20210292842A1 (en) | 2021-09-23 |
EP3449017A4 (en) | 2020-01-08 |
DK3449017T3 (da) | 2022-03-14 |
WO2017189976A1 (en) | 2017-11-02 |
IL262643B2 (en) | 2023-09-01 |
JP2019514930A (ja) | 2019-06-06 |
CA3022377A1 (en) | 2017-11-02 |
IL262643B1 (en) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhao et al. | The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma | |
Teixeira et al. | Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients | |
Yu et al. | MicroRNA-320a inhibits breast cancer metastasis by targeting metadherin | |
BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
Wang et al. | MicroRNA-373 functions as an oncogene and targets YOD1 gene in cervical cancer | |
Hui et al. | miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ERα-positive breast cancer | |
MX2020004567A (es) | Metodos diagnosticos y terapeuticos para el cancer. | |
BR112018069849A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático | |
MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
CL2017001972A1 (es) | Biomarcadores para cáncer pancreático | |
Lattrich et al. | Estrogen receptor β agonists affect growth and gene expression of human breast cancer cell lines | |
Li et al. | The E3 ligase for metastasis associated 1 protein, TRIM25, is targeted by microRNA-873 in hepatocellular carcinoma | |
CO2019011359A2 (es) | Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii | |
Xiong et al. | miR-103 regulates triple negative breast cancer cells migration and invasion through targeting olfactomedin 4 | |
BR112018072286A2 (pt) | medida direcionada de atividade transcricional relacionada a receptores de hormônios | |
UY36200A (es) | Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado | |
BR112015022977A2 (pt) | métodos para predição de risco de metástase em melanoma cutâneo | |
Zhao et al. | MicroRNA‑205 is downregulated in hepatocellular carcinoma and inhibits cell growth and metastasis via directly targeting vascular endothelial growth factor A | |
Zhang et al. | AKR1C2 acts as a targetable oncogene in esophageal squamous cell carcinoma via activating PI3K/AKT signaling pathway | |
Herrera et al. | Silencing of the transcriptional factor ZEB1 alters the steroidogenic pathway, and increases the concentration of testosterone and DHT in DU145 cells | |
BR112019006404A2 (pt) | métodos para diagnóstico e tratamento de câncer de próstata metastático resistente à castração sensível ou resistente a acetato de abiraterona-glicocorticoide | |
Interiano et al. | Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells | |
Carvalho et al. | Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors1 | |
ES2548299A1 (es) | Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama | |
Madathan Kandy et al. | Overexpression and lack of copy number variation in the BMI‑1 gene in human glioma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |